TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02722668
Drug: MMF
Normalized name: MMF
DrugBank: Monomethyl fumarate (DB14219)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both Arms:~Mycophenolate mofetil (MMF) 3 gram/day IV/PO for patients who are ≥ 40 kg divided in 2 or 3 doses. In obese patients (\>125% IBW) 15 mg/kg every 12 hours may be considered. Pediatric patient (\<40 kilograms) will receive MMF at the dose of 15 mg/kg/dose every 8 hours beginning Day -3. MMF dosing will be monitored and altered as clinically appropriate based on institutional guidelines. Patients will be eligible for MMF dosing and pharmacokinetics studies.~Stop MMF at Day +30 or 7 days after engraftment, whichever day is later, if no acute graft versus host disease (GVHD). (Definition of engraftment is 1st day of 3 consecutive days of absolute neutrophil count \[ANC) ≥ 0.5 x 109 /L\]). If no donor engraftment, do not stop MMF.
Study: NCT02670941
Drug: Lavender
Normalized name: lavender
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The lavender oil (LAV-110) was steam distilled from lavender grown in Kashmir Valley in India. The lavender oil contains 53.22% esters, 31.86% monoterpenols, and 4.88% oxides. The aroma of lavender is described as floral, fresh, herbaceous, and sweet.
Study: NCT00068341
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cycle 1-8 Day 1 or 2: 75 mg/m2 IV
Study: NCT02670941
Drug: Orange
Normalized name: orange
DrugBank: Orange (DB10549)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The orange oil (ORG-114) was cold-pressed and steam distilled from oranges in South Africa. The orange oil contains 97.21% monoterpenes, 0.73% aldehydes, and 0.7% monoterpenols. The aroma of orange is described as citrus, fresh, fruity, and sweet.
Study: NCT02670941
Drug: Jojoba
Normalized name: jojoba
DrugBank: Jojoba oil (DB14252)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The jojoba oil is certified organic and pesticide-free pure oil. Jojoba has a mild scent and can be used as a fixative for other essential oils.
Study: NCT03499184
Drug: Flagyl 400 mg Tablet
Normalized name: Flagyl 400 MG Oral Tablet
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systemically administered Metronidazole 400 mg twice daily
Study: NCT01522196
Drug: Varespladib
Normalized name: Varespladib
DrugBank: Varespladib (DB11909)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 48 hour continuous infusion delivered intravenously (IV)at a rate of 110µg/kg/hr.
Study: NCT02722668
Drug: Sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Both Arms:~Adult Dosing: Sirolimus will be administered starting at Day -3 with 8-12 mg oral loading dose followed by single dose 4 mg/day with a target serum concentration of 3 to 12 mg/mL by high-performance liquid chromatography (HPLC) and will be monitored per institutional guidelines. In the absence of acute GVHD sirolimus may be tapered starting at Day +100 and eliminated by Day +180 post-transplantation.~Pediatric Dosing: Sirolimus will be administered starting on Day -3 with an oral loading dose of 10 mg followed by maintenance dosing of 2.5 mg/m\^2/day (Maximum total daily dose of 4mg) as per institutional guidelines. Target serum concentration goals are 3 to 12 mg/mL by high-performance liquid chromatography (HPLC) and will be monitored per institutional guidelines.
Study: NCT00641654
Drug: Pegylated interferon alfa-2a and ribavirin
Normalized name: Pegylated-interferon alfa 2a
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm A: Pegylated interferon alfa-2a Injection, 180 µg sc x 1/w for 48 weeks Ribavirin Tablet 200 mg weight based 5 or 6 per day for 48 weeks
Study: NCT00641654
Drug: Pegylated interferon alfa-2a and ribavirin
Normalized name: Pegylated-interferon alfa 2a
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm B:Pegylated interferon alfa-2a Injection, 180 µg sc x 1/w for 48 weeks Ribavirin Tablet 200 mg weight based 5 or 6 per day for 48 weeks
Study: NCT00641654
Drug: Pegylated interferon alfa-2a and ribavirin
Normalized name: Pegylated-interferon alfa 2a
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm C:Pegylated interferon alfa-2a Injection, 180 µg sc x 1/w for 24 weeks Ribavirin Tablet 200 mg weight based 5 or 6 per day for 24 weeks
Study: NCT02008019
Drug: Everolimus 2.5 mg/day
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Comparison between 2,5 mg/day of Everolimus per os to 10 mg/day, or to no treatment, taken during 30 days before chondrosarcoma surgery
Study: NCT00659113
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00659113
Drug: tegafur-gimeracil-oteracil potassium
Normalized name: tegafur
DrugBank: Oteracil (DB03209)
Approvals — FDA: no, EMA: yes, PMDA: no
Study: NCT02008019
Drug: Everolimus 10 mg/day
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Comparison between 10 mg/day of Everolimus per os to 2.5 mg/day, or to no treatment taken during 30 days before chondrosarcoma surgery
Study: NCT00950404
Drug: Viagra 50 mg tablet
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercial tablet, 50 mg, single dose administered with water
Study: NCT00376675
Drug: methylphenidate hydrochloride
Normalized name: Methylphenidate Hydrochloride
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally
Study: NCT01067274
Drug: Vesanoid (ATRA)
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 45 mg/m2/day in two divided doses from D8 to D28
Study: NCT01067274
Drug: AZACITIDINE (VIDAZA)
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 75 mg/m2/12h SC from D1 to D5
Study: NCT01067274
Drug: CYTARABINE
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cytarabine : 60 mg/m2/12h SC from D1 to D5
Study: NCT03774914
Drug: Alemtuzumab (GZ402673)
Normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pharmaceutical form:Concentrate for solution for infusion Route of administration: Intravenous infusion
Study: NCT00736450
Drug: vincristine sulfate
Normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00736450
Drug: prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally
Study: NCT00078572
Drug: lapatinib (GW572016)
DrugBank: Lapatinib (DB01259)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Lapatinib 1250 mg orally once daily
Study: NCT02729701
Drug: Duavee
Normalized name: Duavee
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Once daily tablet of Duavee (Bazedoxifene (20 mg) plus conjugated estrogen (0.45 mg))
Study: NCT02943668
Drug: Deferasirox
Normalized name: Deferasirox
DrugBank: Deferasirox (DB01609)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT00790192
Drug: Lurasidone
Normalized name: Lurasidone
DrugBank: Lurasidone (DB08815)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lurasidone 80 mg tablets
Study: NCT00790192
Drug: Lurasidone
Normalized name: Lurasidone
DrugBank: Lurasidone (DB08815)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lurasidone 4 40 mg tablets
Study: NCT00790192
Drug: Quetiapine XR
Normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quetiapine XR 600mg
Study: NCT00332644
Drug: nicotine patch
Normalized name: Nicotine Patch
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: used according to FDA package label
Study: NCT00332644
Drug: nicotine lozenge
Normalized name: nicotine Lozenge Product
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: used according to FDA-approved package directions
Study: NCT00332644
Drug: nicotine patch + nicotine lozenge
Normalized name: nicotine Oral Lozenge
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: dosage of both according to FDA-approved dosing schedule
Study: NCT00332644
Drug: bupropion
Normalized name: Bupropion
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: dosage according to FDA-approved instructions
Study: NCT00332644
Drug: bupropion + lozenge
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: dosage according to FDA approved standard instructions
Study: NCT01281813
Drug: Darunavir
Normalized name: Darunavir
DrugBank: Darunavir (DB01264)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive darunavir (per parent study) as oral suspension.
Study: NCT01281813
Drug: Ritonavir
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive ritonavir (per parent study) as oral solution/suspension.
Study: NCT04282668
Drug: TAS1440 + ATRA
Normalized name: ATRA
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Form: Capsule or Tablet Route of Administration: Oral
Study: NCT02468726
Drug: Fleet
Normalized name: Fleet Enema
DrugBank: Phenylephrine (DB00388)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fleet enema administered to cleanse the bowel bewteen 1 and 3 hours prior to flexible sigmoidoscopy
Study: NCT00149903
Drug: Mycophenolate sodium (enteric coated)
Normalized name: mycophenolate
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03956966
Drug: TQL block with saline
Normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: drug: saline 21 ml 0.9% normal saline administered on each side as bilateral TQL blocks Drug: fentanyl With induction of general anaesthesia, fentanyl (1 microgram.kg) will be given. Intraoperatively, fentanyl boluses (0.5 microgram.kg) will be given in case of increase in intraoperative mean arterial blood pressure or heart rate of more than 20% of baseline for longer than 5 minutes.~Drug: Paracetamol Paracetamol infusion (15 mg.kg) will be given by intravenous infusion after induction of general anesthesia. Postoperatively, 1 g of paracetamol will be given by intravenous infusion to all cases every 8 hours.~Drug: Ketorolac analgesia In PACU Ketorolac 30 mg ampoule will be given by intravenous infusion to all cases Drug: Nalbuphine Nalbuphine boluses 0.1 mg. /kg will be given as rescue analgesia if VAS is more than3.~Device: ultrasound-guided nerve block Transmuscular quadratus lumborum block, ultrasound-guided
Study: NCT03597841
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who are given combination therapy will be allocated to this group.
Study: NCT00075491
Drug: fenretinide
Normalized name: FENRETINIDE
DrugBank: Fenretinide (DB05076)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given orally
Study: NCT03956966
Drug: TQL block with Bupivacaine
Normalized name: Ivy Block
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug: saline~1mL 0.9% normal saline administered on each side as bilateral TQL blocks drug: Bupivacaine 20 ml Bupivacaine hydrochloride 0.25% administered on each side as bilateral TQL blocks Drug: fentanyl With induction of general anaesthesia, fentanyl (1 microgram.kg) will be given. Intraoperatively, fentanyl boluses (0.5 microgram.kg) will be given in case of increase in intraoperative mean arterial blood pressure or heart rate of more than 20% of baseline for longer than 5 minutes.~Drug: Paracetamol 15 mg.kg will be given by intravenous infusion after induction of general anesthesia. Postoperatively, 1 g of paracetamol will be given to all cases every 8 hours.~Drug: Ketorolac In PACU Ketorolac 30 mg ampoule will be given by intravenous infusion to all cases Drug: Nalbuphine Nalbuphine boluses 0.1 mg. /kg will be given as rescue analgesia if VAS is more than 3.~Device: ultrasound-guided nerve block Transmuscular quadratus lumborum block
Study: NCT00238446
Drug: EC-MPS
Normalized name: 6 MP
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02104648
Drug: moxifloxacin
Normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400 mg oral dose given on Day 1 or 11
Study: NCT03956966
Drug: TQL block with Bupivacaine and dexamethasone
Normalized name: bupivacaine and meloxicam
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug: dexamethasone~1 mL dexamethasone 4mg administered on each side as bilateral TQL blocks drug: Bupivacaine 20 ml Bupivacaine hydrochloride 0.25% administered on each side as bilateral TQL blocks Drug: fentanyl With induction of general anaesthesia, fentanyl (1 microgram.kg) will be given. Intraoperatively, fentanyl boluses (0.5 microgram.kg) will be given in case of increase in MBP or HR of more than 20% of baseline for longer than 5 minutes.~Drug: Paracetamol Paracetamol infusion (15 mg.kg) will be given by intravenous infusion after induction of general anesthesia. Postoperatively, 1 g of paracetamol will be given by intravenous infusion to all cases every 8 hours.~Drug: Ketorolac In PACU Ketorolac 30 mg ampoule will be given by intravenous infusion to all cases Drug: Nalbuphine Nalbuphine boluses 0.1 mg. /kg will be given as rescue analgesia if VAS is more than 3.~Device: ultrasound-guided nerve block Transmuscular quadratus lumborum block
Study: NCT00558363
Drug: Avodart
Normalized name: Avodart
DrugBank: Dutasteride (DB01126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5 mg administered orally once daily
Study: NCT02937792
Drug: intrathecal 15 mg bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: spinal anesthesia with a large dose of bupivacaine 0.5% in elective caesarean section
Study: NCT00579189
Drug: Moxifloxacin otic solution
Normalized name: moxifloxacin Ophthalmic Solution
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4 drops into the infected ear(s) twice daily (morning and evening) for 7 days
Study: NCT04192955
Drug: Acetyl Salicylate
Normalized name: acetyl salicylate
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets
Study: NCT02935530
Drug: s-LMWH
Normalized name: S-2
DrugBank: Racepinephrine (DB11124)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2125KU, subcutaneous injection of 5-10 days
Study: NCT02935530
Drug: Argatroban
Normalized name: Argatroban
DrugBank: Argatroban (DB00278)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20mg, injection for 5-10 days
Study: NCT00250237
Drug: Haloperidol
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Haloperidol 1mg twice daily during 72hours
Study: NCT01539655
Drug: vandetanib
Normalized name: Vandetanib
DrugBank: Vandetanib (DB05294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tablets, 300 mg, single dose
Study: NCT01539655
Drug: omeprazole
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral capsules, 40 mg, multiple doses
Study: NCT01539655
Drug: ranitidine
Normalized name: Ranitidine
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tables, 150 mg, multiple doses
Study: NCT01616654
Drug: Tazarotene 0.1% gel
Normalized name: TAZAROTENE 0.1% GEL,TOP
DrugBank: Tazarotene (DB00799)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tazarotene 0.1% gel applied once daily
Study: NCT02817217
Drug: Valsartan
Normalized name: Valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: SP2086 will be administered orally (by mouth) as100mg on Days 4, 5, 6, 7, and 8 and Valsartan will be administered orally as two 80mg tablets on Days 1 and 8. Both SP2086 and Valsartan tablets will be taken with 8 ounces (240 mL) of water.
Study: NCT00199108
Drug: Depocyt
Normalized name: DepoCyt
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00199108
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02797249
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low dose aspirin（100mg）per day starting between 12+ and 20 weeks of pregnancy until 34 weeks of pregnancy,taking at night.
Study: NCT02773017
Drug: Dexmedetomidine A
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: initial dose was 1.0 μg/kg dexmedetomidine, with dose adjustment intervals of 0.1μg/kg in first three turning points and 0.05μg/kg in the last three turning points.
Study: NCT02773017
Drug: Dexmedetomidine B
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: initial dose was 1.0 μg/kg dexmedetomidine, with dose adjustment intervals of 0.1μg/kg in first three turning points and 0.05μg/kg in the last three turning points.
Study: NCT02773017
Drug: Dexmedetomidine C
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: initial dose was 1.0 μg/kg dexmedetomidine, with dose adjustment intervals of 0.1μg/kg in first three turning points and 0.05μg/kg in the last three turning points.
Study: NCT01203618
Drug: Farletuzumab
Normalized name: Farletuzumab
DrugBank: Farletuzumab (DB05595)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Farletuzumab initial loading dose 5.0 mg/kg intravenous followed by 2.5 mg/kg intravenous for all subsequent doses every 2 weeks for up to 12 months.
Study: NCT02169154
Drug: 3% Menthol
Normalized name: CAPSAICIN 0.83 mg in 1 g / MENTHOL, (+)- 0.03 g in 1 g TOPICAL PATCH [3% Menthol plus 0.083% Capsaicin Pain Relief Patch (2 Patches/Pouch)]
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% Menthol
Study: NCT02169154
Drug: 0.09% Menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.09% Menthol
Study: NCT04414163
Drug: IMC-001
Normalized name: IMC-18F1
DrugBank: Icrucumab (DB14824)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose level for enrollment subject (IMC-001 20mg/kg every 2 weeks)
Study: NCT02820454
Drug: AGuIX
Normalized name: AGuIX
DrugBank: AGuIX (DB18189)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single intravenous injection on day 1. Dose level 1: 15mg/kg; Dose level 2: 30mg/kg, Dose level 3: 50mg/kg; Dose level 4: 75mg/kg; Dose level 5: 100mg/kg
Study: NCT02169154
Drug: 0.2% Sodium Lauryl Sulfate
DrugBank: Sodium lauryl sulfate (DB00815)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.2% Sodium Lauryl Sulfate
Study: NCT00762099
Drug: Pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pre-operative dose 150 mg Post-operative dose 75 mg BID
Study: NCT02564068
Drug: Oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: To test that intranasal oxytocin administration blunts the deleterious hypoxia/hypercapnia induced changes in heart rate that occur during nocturnal apnea in patients with OSA, we will examine the changes in heart rate in a group of patients that have recently been diagnosed with OSA. 8 subjects that have recently undergone a standard in the sleep-lab diagnostic polysomnography (per standard of care medical guidelines, and not for research purposes) and have been diagnosed with OSA will be recruited into a study to assess the beneficial effects of oxytocin treatment.
Study: NCT02738346
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous administration of Carboplatin AUC 5 at Day 1, Every 3 weeks, maximum 6 cycles
Study: NCT00000251
Drug: 0.2% isoflurane
DrugBank: Isoflurane (DB00753)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03456817
Drug: Treatment Arm - high dose ATG
Normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients agreeing to high dose ATG will be treated with 2 mg/kg daily on days -4 to 0. On days -4, -3 \& -2, ATG will be infused after fludarabine \& busulfan infusion. ATG will be infused over a minimum of 6 hrs on day -4 \& over at least 4 hrs on days -3, -2, -1 \& 0. Dose is based on actual body wt, \& rounded to nearest vial-Thymoglobulin is supplied in 25 mg vials, except if rounding would result in \>5% difference from calculated dose. Foothills Medical Center Unit 57 standard practice followed for ATG infusion. ATG premeds include methylprednisolone, diphenhydramine, and an antipyretic. Meperidine 25-50 mg IVPB every 4 hours will be given as needed for rigors. MTX is given 15 mg/m2 IV on day +1 \& 10 mg/m2 on days +3, +6 \& +11 posttransplant. First dose of methotrexate is given on day +1, at least 24 hrs following end of infusion of stem cell product.
Study: NCT03983889
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam is used as a common medication for sedation in all groups.
Study: NCT03983889
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine is used for sedation in bronchoscopy with less impact on respiration.
Study: NCT03983889
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol is used for sedation with high efficacy but more side effect on respiration than dexmedetomidine.
Study: NCT00923676
Drug: fenofibrate
Normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: pill 145 mg, 145 mg/day, for 12 months
Study: NCT02738346
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous administration of 100mg/m²/day of Etoposide, Day 1 to Day 3 Every 3 weeks, maximum 6 cycles
Study: NCT02738346
Drug: Topotecan
Normalized name: Topotecan
DrugBank: Topotecan (DB01030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Per os administration of 2.3 mg / m2 of Topotecan, Day 1 to Day 5 Every 3 weeks, maximum 6 cycles
Study: NCT03949686
Drug: Saline Solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5 ml/kg saline
Study: NCT03949686
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5 ml/kg %0.25 bupivacaine
Study: NCT02301221
Drug: Vancomycin and bowel lavage
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: An initial vancomycin regimen (500 mg orally two times per day for 3 days), followed by bowel lavage before the infusion of a solution of donor fecal microbiota.
Study: NCT00390429
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV